Reviva Pharmaceuticals Holdings, Inc.NASDAQ:RVPH
- LAST PRICE1.6700
- TODAY'S CHANGE (%)-0.0400 (-2.3392%)
- Bid / Lots1.6100/ 10
- Ask / Lots1.7100/ 9
- Open / Previous Close1.7100 / 1.7100
- Day Range
- 52 Week Range
- Volume305,845
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RVPH |
|---|---|---|
| 09:32 ET | 5417 | 1.71 |
| 09:36 ET | 10824 | 1.7 |
| 09:38 ET | 500 | 1.7 |
| 09:39 ET | 200 | 1.7 |
| 09:41 ET | 100 | 1.7 |
| 09:43 ET | 47926 | 1.65 |
| 09:45 ET | 4400 | 1.65 |
| 09:48 ET | 500 | 1.65 |
| 09:50 ET | 601 | 1.6679 |
| 09:52 ET | 200 | 1.6577 |
| 09:54 ET | 2115 | 1.67 |
| 09:56 ET | 700 | 1.6605 |
| 09:57 ET | 300 | 1.6605 |
| 09:59 ET | 200 | 1.665 |
| 10:01 ET | 1450 | 1.665 |
| 10:03 ET | 700 | 1.665 |
| 10:06 ET | 800 | 1.6601 |
| 10:08 ET | 200 | 1.6641 |
| 10:10 ET | 100 | 1.6641 |
| 10:12 ET | 1421 | 1.665 |
| 10:14 ET | 8275 | 1.66 |
| 10:19 ET | 500 | 1.665 |
| 10:21 ET | 100 | 1.66 |
| 10:30 ET | 600 | 1.67 |
| 10:32 ET | 300 | 1.67 |
| 10:33 ET | 226 | 1.664 |
| 10:35 ET | 100 | 1.665 |
| 10:39 ET | 200 | 1.6609 |
| 10:50 ET | 700 | 1.6606 |
| 10:55 ET | 1774 | 1.665 |
| 10:57 ET | 289 | 1.6698 |
| 11:04 ET | 200 | 1.67 |
| 11:08 ET | 500 | 1.67 |
| 11:11 ET | 812 | 1.66 |
| 11:15 ET | 280 | 1.665 |
| 11:18 ET | 100 | 1.66 |
| 11:24 ET | 600 | 1.668 |
| 11:26 ET | 2735 | 1.6601 |
| 11:27 ET | 200 | 1.665 |
| 11:29 ET | 1900 | 1.6699 |
| 11:36 ET | 19749 | 1.665 |
| 11:42 ET | 950 | 1.66 |
| 11:44 ET | 200 | 1.66 |
| 11:45 ET | 1000 | 1.664 |
| 11:47 ET | 100 | 1.665 |
| 11:51 ET | 100 | 1.665 |
| 11:54 ET | 124 | 1.665 |
| 11:56 ET | 1000 | 1.665 |
| 11:58 ET | 4678 | 1.6699 |
| 12:00 ET | 18134 | 1.67 |
| 12:02 ET | 1416 | 1.67 |
| 12:03 ET | 100 | 1.67 |
| 12:05 ET | 100 | 1.66 |
| 12:07 ET | 100 | 1.66 |
| 12:09 ET | 117 | 1.67 |
| 12:18 ET | 856 | 1.67 |
| 12:23 ET | 100 | 1.68 |
| 12:30 ET | 199 | 1.6601 |
| 12:39 ET | 3400 | 1.67 |
| 12:43 ET | 3282 | 1.665 |
| 12:48 ET | 100 | 1.665 |
| 12:50 ET | 125 | 1.665 |
| 12:54 ET | 200 | 1.665 |
| 12:56 ET | 1000 | 1.665 |
| 12:57 ET | 2699 | 1.665 |
| 01:01 ET | 100 | 1.665 |
| 01:03 ET | 1160 | 1.67 |
| 01:06 ET | 700 | 1.6697 |
| 01:08 ET | 300 | 1.665 |
| 01:10 ET | 800 | 1.665 |
| 01:12 ET | 100 | 1.67 |
| 01:24 ET | 200 | 1.665 |
| 01:35 ET | 700 | 1.67 |
| 01:42 ET | 100 | 1.665 |
| 01:44 ET | 200 | 1.665 |
| 01:50 ET | 119 | 1.665 |
| 01:51 ET | 137 | 1.665 |
| 01:53 ET | 100 | 1.665 |
| 01:57 ET | 600 | 1.665 |
| 02:00 ET | 12044 | 1.67 |
| 02:04 ET | 200 | 1.67 |
| 02:06 ET | 600 | 1.665 |
| 02:08 ET | 300 | 1.665 |
| 02:09 ET | 300 | 1.665 |
| 02:13 ET | 5800 | 1.67 |
| 02:18 ET | 5900 | 1.665 |
| 02:20 ET | 50367 | 1.625 |
| 02:22 ET | 2837 | 1.625 |
| 02:24 ET | 3140 | 1.62 |
| 02:27 ET | 1400 | 1.625 |
| 02:29 ET | 7331 | 1.635 |
| 02:33 ET | 900 | 1.65 |
| 02:36 ET | 400 | 1.66 |
| 02:38 ET | 300 | 1.66 |
| 02:40 ET | 100 | 1.66 |
| 02:42 ET | 411 | 1.6562 |
| 02:44 ET | 300 | 1.651 |
| 02:45 ET | 200 | 1.66 |
| 02:47 ET | 300 | 1.6511 |
| 02:49 ET | 300 | 1.6589 |
| 02:51 ET | 1255 | 1.66 |
| 02:54 ET | 300 | 1.66 |
| 02:56 ET | 600 | 1.67 |
| 02:58 ET | 500 | 1.665 |
| 03:00 ET | 900 | 1.67 |
| 03:02 ET | 600 | 1.6601 |
| 03:09 ET | 200 | 1.66 |
| 03:18 ET | 100 | 1.665 |
| 03:25 ET | 213 | 1.665 |
| 03:27 ET | 200 | 1.67 |
| 03:32 ET | 726 | 1.6601 |
| 03:36 ET | 100 | 1.665 |
| 03:38 ET | 100 | 1.67 |
| 03:39 ET | 200 | 1.665 |
| 03:41 ET | 456 | 1.665 |
| 03:45 ET | 400 | 1.67 |
| 03:48 ET | 2000 | 1.6699 |
| 03:52 ET | 1800 | 1.665 |
| 03:54 ET | 1200 | 1.665 |
| 03:56 ET | 972 | 1.67 |
| 03:57 ET | 1961 | 1.67 |
| 03:59 ET | 4482 | 1.67 |
Yesterday
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH, from 22 hours ago by Dow Jones
22 hours ago by Dow JonesROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation - RVPH, from 4:06PM ET on Thursday May 16, 2024 by Dow Jones
4:06PM ET on Thursday May 16, 2024 by Dow Jones
May 15, 2024
RVPH LOSS ALERT: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation - RVPH, from 11:49AM ET on Wednesday May 15, 2024 by Dow Jones
11:49AM ET on Wednesday May 15, 2024 by Dow JonesReviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia, from 8:00AM ET on Wednesday May 15, 2024 by Dow Jones
8:00AM ET on Wednesday May 15, 2024 by Dow Jones
May 14, 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH, from 9:00PM ET on Tuesday May 14, 2024 by Dow Jones
9:00PM ET on Tuesday May 14, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Reviva Pharmaceuticals Holdings, Inc. | 47.7M | -1.0x | --- |
Carmell Corp | 47.3M | -1.3x | --- |
Gain Therapeutics Inc | 48.6M | -1.5x | --- |
NextCure Inc | 46.2M | -0.7x | --- |
Immuneering Corp | 45.7M | -0.8x | --- |
IN8BIO, Inc. | 44.9M | -1.1x | --- |
Company Information
Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and seeks to commercialize therapeutics for diseases representing unmet medical needs. The Company’s pipeline focuses on the central nervous system, respiratory and metabolic diseases. Its pipeline includes two drug candidates, RP5063 (brilaroxazine) and RP1208. Its lead drug candidate, brilaroxazine, is in clinical development and is to treat multiple neuropsychiatric indications. These include schizophrenia, bipolar disorder (BD), major depressive disorder (MDD), attention-deficit/hyperactivity disorder (ADHD), behavioral and psychotic symptoms of dementia or Alzheimer’s disease (BPSD), and Parkinson’s disease psychosis. Brilaroxazine is also ready for clinical development for two respiratory indications, including pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). Its RP1208 drug candidate is a triple reuptake inhibitor (TRI).
Contact Information
- Headquarters
- 10080 N Wolfe Road, Suite Sw3-200CUPERTINO, CA, United States 95014
- Phone
- 408-501-8881
- Fax
- 408-904-6270
Executives
- Independent Chairman of the Board
- Parag Saxena
- President, Chief Executive Officer, Director
- Laxminarayan Bhat
- Chief Financial Officer
- Narayan Prabhu
- Independent Director
- Leslie Funtleyder
- Independent Director
- Richard Margolin
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $47.7M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 27.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.08 |
EPS | $-1.66 |
Book Value | $0.20 |
P/E Ratio | -1.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
